“…17 These inhibitors, however, still suffer from low membrane permeability and poor ability to cross the BBB as a result of their high basicity and/or polarity. In the past few years our group has pursued various medicinal chemistry approaches to improve the pharmacokinetic values of nNOS inhibitors, such as incorporating intramolecular hydrogen bonds ( 1 ), 18 converting to prodrugs ( 2 ), 19 modulating the amine basicity ( 3 ), 20 and replacing an essential pharmacophore, such as replacement of the 2-aminopyridine with a 2-imidazolylpyrimidine ( 4 ) 21 or 2-aminoquinoline ( 5 ) 22 (Figure 1). Although some pharmacokinetic improvement has been achieved, these approaches can result in a diminution in activity, especially for human nNOS, the ultimate target for neurodegenerative diseases, and in the selectivity over human eNOS.…”